The incidence of osteonecrosis of the jaw (ONJ) in the population is low, but specifics are unknown. Potential risk factors include bisphosphonate treatment, steroid treatment, osteoporosis, and head/neck radiation. This Dental Practice-Based Research Network study estimated ONJ incidence and odds ratios from bisphosphonate exposure and other risk factors using a key word search and manual chart reviews of electronic records for adults aged ≥ 35 yrs enrolled during 1995–2006 in two large health-care organizations. We found 16 ONJ cases among 572,606 cohort members; seven additional cases were identified through dental plan resources. Among 23 cases (0.63 per 100,000 patient years), 20 (87%) had at least one risk factor, and six (26%) had received oral bisphosphonates. Patients with oral bisphosphonates were 15.5 (CI, 6.0–38.7) more likely to have ONJ than non-exposed patients; however, the sparse number of ONJ cases limits firm conclusions and suggests that the absolute risks for ONJ from oral bisphosphonates is low.
American Association of Oral and Maxillofacial Surgeons (2007). Position paper on bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg65:369-376.
2.
BilezikianJP (2006). Osteonecrosis of the jaw–do bisphosphonates pose a risk?N Engl J Med355:2278-2281.
3.
CartsosVMZhuSZavrasAI (2008). Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc139:23-30.
4.
EdwardsBJGounderMMcKoyJMBoydIFarrugiaMMiglioratiC. (2008). Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol9:1166-1172.
5.
Estefania-FrescoRPonte-FernándezNAguirre-UrizarJM (2006). Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Pathol Oral Cir Bucal11:E456-E461.
6.
GrbicJTLandesbergRLinSMesenbrinkPReidIRLeungPC. (2008). Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc139:32-40.
7.
HessLMJeterJMBenham-HutchinsMAlbertsDS (2008). Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med121:475-483.
8.
HewittCFarahCS (2007). Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med36:319-328.
9.
KhanAASandorGKDoreEMorrisonADAlsahliMAminF. (2008). Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 35:1391-1397; errata in J Rheumatol 35:1688 and J Rheumatol 35:2084, 2008.
10.
KhoslaSBurrDCauleyJDempsterDWEbelingPRFelsenbergD. (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res22:1479-1491.
11.
MarxRESawatariYFortinMBroumandV (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg63:1567-1575.
12.
MarxRECilloJEUlloaJJ (2007). Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg65:2397-2410.
13.
MavrokokkiTChengASteinBGossA (2007). Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg65:415-423.
14.
McMahonREBouquotJEGlueckCJSpolnikKJAdamsWR (2004). Osteonecrosis: a multifactorial etiology. J Maxillofac Surg62:904-905.
15.
MiglioratiCACasigliaJEpsteinJJacobsenPLSiegelMAWooSB (2005). Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc136:1658-1668; erratum in J Am Dent Assoc 134:26, 2006.
16.
MuradOMAroraSFaragAFGuberHA (2007). Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr Pract13:232-238.
17.
PazianasMMillerPBlumentalsWABernalMKothawalaP (2007). A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther29:1548-1558.
18.
PazianasMBlumentalsWAMillerPD (2008). Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int19:773-779.
19.
QaseemASnowVShekellePHopkinsRForcieaMOwensDK (2008). Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med149:404-415.
20.
ReidIRBollandMJGreyAB (2007). Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?Bone41:318-320.
21.
ReszkaAARodanGA (2003). Bisphosphonate mechanism of action. Curr Rheumatol Rep5:65-74.
22.
RizzoliRBurletNCahallDDelmasPDEriksenEFFelsenbergD. (2008). Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone42:841-847.
23.
RuggieroSGralowJMarxREHoffAOSchubertMMHurynJM. (2006). Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract2:7-14.
24.
WilkinsonGSKuoYFFreemanJLGoodwinJS (2007). Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst99:1016-1024.
25.
WooSBHellsteinJWKalmarJR (2006). Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med144:753-761; erratum in Ann Intern Med 145:235, 2006.
26.
YaromNShoshaniYHamedWRegevEEladS (2007). Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporosis Int18:1363-1370.
